SequelSEC

Oncotelic Therapeutics, Inc. OTLC

Pharmaceutical Preparations · CIK 0000908259 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$250.00K
Fiscal year ended 2026-06-30
Operating income
-$843.56K
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Oncotelic Therapeutics, Inc. (OTLC) reported revenue of $250.00K and net income of $388.15K for the fiscal year ended 2026-06-30. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from Oncotelic Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Oncotelic Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302023-12-312023-09-302020-12-312020-09-302020-06-302020-03-31
Revenue$250.00K$0$70.00K$0$0$1.40M$340.86K
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$843.56K-$113.46K$14.48K-$3.33M-$1.62M$13.84K-$2.65M
Net income$388.15K-$735.98K$115.31K-$3.44M-$1.99M$582.09K-$4.66M
Research & development$345$11.00K$21.22K$2.57M$936.20K$482.14K$312.00K
Weighted-average diluted sharesshares 467.91MUnavailableshares 397.78MUnavailableUnavailableshares 94.74MUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$0.00Unavailable$0.00UnavailableUnavailable$0.01Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$1.09M$102.47K$34.30K$759.88K$680.08K$904.02K$2.68M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Oncotelic Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302023-12-312023-09-302020-12-312020-09-302020-06-302020-03-31
Cash & equivalentsUnavailable$170.40KUnavailable$474.02K$1.36M$660.90K$183.44K
Total assets$394.75M$30.01M$30.10M$23.66M$24.63M$24.01M$23.60M
Current assets$1.46M$271.74K$365.54K$615.64K$1.49M$783.02K$274.15K
Total liabilities$131.31M$18.40MUnavailableUnavailableUnavailableUnavailableUnavailable
Current liabilities$17.91M$16.50M$17.11M$11.18M$8.76M$8.22M$8.48M
Total equity incl. NCI$263.44M$11.61M$12.09M$12.48M$15.86M$15.80M$15.11M
Temporary (mezzanine) equityUnavailableUnavailable$899.10KUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivable$2.06K$18.98K$18.98K$19.75K$19.75K$19.75K$19.75K
Goodwill$2.79M$5.99M$5.99M$21.06M$21.06M$21.06M$21.06M
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailable$1.94M$2.02M$1.74M$1.74M

Cash flow

Oncotelic Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302023-12-312023-09-302020-12-312020-09-302020-06-302020-03-31
Operating cash flowUnavailable-$372.62KUnavailable-$1.49M-$1.58M$227.47K$31.47K
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Financing cash flowUnavailable$275.00KUnavailable$599.52K$2.30M$250.00K$70.00K
Net change in cashUnavailable-$97.62KUnavailable-$888.17K$721.28K$477.47K$101.47K
Stock-based compensationUnavailableUnavailableUnavailable$0$0$0$2.15M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Oncotelic Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302023-12-312023-09-302020-12-312020-09-302020-06-302020-03-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-337.4%Unavailable20.7%UnavailableUnavailable1.0%-777.1%
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailable0.0%630.1%
Current ratio0.08x0.02x0.02x0.06x0.17x0.10x0.03x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net margin155.3%Unavailable164.7%UnavailableUnavailable41.6%-1366.5%
R&D / revenue0.1%Unavailable30.3%UnavailableUnavailable34.4%91.5%
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open OTLC in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-04-15View SEC filing
10-Q · Filed 2025-11-17View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.